John Mathew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John Mathew has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Kwok-Leung Cheung
School of Medicine, University of Nottingham, Nottingham, UK
5 shared publications J.F.R. Robertson
Royal Derby Hospital Centre, Derby, UK
4 shared publications- Amit Agrawal
Department of Surgery, University of Cambridge, Cambridge, UK
3 shared publications - Ian Ogilvie Ellis
Department of Histopathology Nottingham University Hospitals Nottingham UK
3 shared publications N. Y. Haboubi
Department of Pathology Trafford General Hospital Manchester United Kingdom
3 shared publications- Avanish Saklani
Division of Colo‐Rectal and Peritoneal Surface Oncology, Department of Surgical Oncology Tata Memorial Hospital, Homi Bhabha National Institute Mumbai India
2 shared publications
Latest Publications
- 1 February 2017
- Published by Elsevier in The Breast
- Vol. 31, 181-185
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ
- 1 February 2017
- Published by Elsevier in The Breast
- Vol. 31, 181-185
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ
- 1 December 2014
- Published by Elsevier in The Surgeon
- Vol. 12 (6) , 307-309
Symmetrisation procedures in breast reconstruction patients constitute a rising workload in our DGH
- 1 December 2014
- Published by Elsevier in The Surgeon
- Vol. 12 (6) , 307-309
Symmetrisation procedures in breast reconstruction patients constitute a rising workload in our DGH
- Open Access
- 1 October 2014
- Published by Elsevier in The Breast
- Vol. 23 (5) , 567-572
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer
- 1 October 2014
- Published by Elsevier in The Breast
- Vol. 23 (5) , 567-572
Open AccessPilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer
- 23 August 2014
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 147 (3) , 671-674
A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts
Ductal carcinoma is the commonest histological type found in invasive breast carcinomas and may be associated with worse prognosis, when compared to non-ductal carcinoma. Older patients tend to display more favourable tumour biology than younger patients. This study aimed to investigate the significance of histological type and its relationship with clinical outcome in the older group. A total of 808 older (≥70 years) women with early operable primary breast cancer underwent surgery as their primary treatment, followed by optimal adjuvant therapies, in the Nottingham Breast Unit between 1973 and 2009. The histological types of the surgical specimens were reviewed and compared with those in a previously characterised younger (N = 1,733), in terms of distribution and correlation with clinical outcome. Ductal type was associated with a significantly worse clinical outcome when compared to non-ductal type in the older group in terms of 10-year rates of metastasis-free survival (75 vs 79 %, p = 0.028) and overall survival (44 vs 52 %; p = 0.015). Similar worse clinical outcome was found with the ductal type in the younger group in terms of 10-year rates of metastasis-free survival (65 vs 79 %; p = 0.001) and overall survival (60 vs 78 %; p = 0.001). For all patients with ductal type carcinomas, the older series showed significantly better 10-year metastasis-free survival (75 vs 65 %, p < 0.001) and breast cancer-specific survival (75 vs 69 %, p = 0.025) when compared to the younger series. In both old and the young, ductal cancers were associated with poor survival outcome when compared to non-ductal cancers. When compared to their younger counterparts, older patients with ductal type carcinomas had better metastasis-free and breast cancer-specific survival rates (their lower overall survival was likely to be due to death from other causes), despite having a lower likelihood of receiving adjuvant systemic therapy.
- 23 August 2014
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 147 (3) , 671-674
A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts
Ductal carcinoma is the commonest histological type found in invasive breast carcinomas and may be associated with worse prognosis, when compared to non-ductal carcinoma. Older patients tend to display more favourable tumour biology than younger patients. This study aimed to investigate the significance of histological type and its relationship with clinical outcome in the older group. A total of 808 older (≥70 years) women with early operable primary breast cancer underwent surgery as their primary treatment, followed by optimal adjuvant therapies, in the Nottingham Breast Unit between 1973 and 2009. The histological types of the surgical specimens were reviewed and compared with those in a previously characterised younger (N = 1,733), in terms of distribution and correlation with clinical outcome. Ductal type was associated with a significantly worse clinical outcome when compared to non-ductal type in the older group in terms of 10-year rates of metastasis-free survival (75 vs 79 %, p = 0.028) and overall survival (44 vs 52 %; p = 0.015). Similar worse clinical outcome was found with the ductal type in the younger group in terms of 10-year rates of metastasis-free survival (65 vs 79 %; p = 0.001) and overall survival (60 vs 78 %; p = 0.001). For all patients with ductal type carcinomas, the older series showed significantly better 10-year metastasis-free survival (75 vs 65 %, p < 0.001) and breast cancer-specific survival (75 vs 69 %, p = 0.025) when compared to the younger series. In both old and the young, ductal cancers were associated with poor survival outcome when compared to non-ductal cancers. When compared to their younger counterparts, older patients with ductal type carcinomas had better metastasis-free and breast cancer-specific survival rates (their lower overall survival was likely to be due to death from other causes), despite having a lower likelihood of receiving adjuvant systemic therapy.
- 1 February 2009
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 35 (2) , 113-122
Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions
- 1 February 2009
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 35 (2) , 113-122
Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions
- 2 March 2008
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 113 (2) , 403-407
Primary endocrine therapy in locally advanced breast cancers—the Nottingham experience
Introduction There are trials comparing different neoadjuvant chemotherapy regimens for locally advanced primary breast cancer (LAPC). Few studies have evaluated alternative therapeutic approaches towards LAPC. A previous trial from our institute in LAPC patients unselected for oestrogen receptor (ER) status, comparing primary endocrine therapy versus multimodal treatment, showed no difference in breast cancer related deaths or overall survival. We report our experience of primary endocrine therapy in ER+ LAPC. Methods Between 1988 and 2007, 195 ER+, non-inflammatory LAPC patients were treated with primary endocrine agents in our institute, due to patient choice, being unfit for chemotherapy, or recruitment into the above mentioned trial. All patients had disease assessable by UICC criteria. Results Median age was 69 years. The median follow-up was 61 months. 154 patients (79%) received endocrine treatment alone. 185 patients (95%) derived clinical benefit (complete response/ partial response/ stable disease) for ≥6 months from primary endocrine therapy. Overall 5-year survival was 76% and 5-year breast cancer specific survival was 86%. Conclusion In selected group of ER+ LAPC patients, primary endocrine treatment achieves excellent survival outcome and is a viable alternative to other modalities of treatment.
- 2 March 2008
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 113 (2) , 403-407
Primary endocrine therapy in locally advanced breast cancers—the Nottingham experience
Introduction There are trials comparing different neoadjuvant chemotherapy regimens for locally advanced primary breast cancer (LAPC). Few studies have evaluated alternative therapeutic approaches towards LAPC. A previous trial from our institute in LAPC patients unselected for oestrogen receptor (ER) status, comparing primary endocrine therapy versus multimodal treatment, showed no difference in breast cancer related deaths or overall survival. We report our experience of primary endocrine therapy in ER+ LAPC. Methods Between 1988 and 2007, 195 ER+, non-inflammatory LAPC patients were treated with primary endocrine agents in our institute, due to patient choice, being unfit for chemotherapy, or recruitment into the above mentioned trial. All patients had disease assessable by UICC criteria. Results Median age was 69 years. The median follow-up was 61 months. 154 patients (79%) received endocrine treatment alone. 185 patients (95%) derived clinical benefit (complete response/ partial response/ stable disease) for ≥6 months from primary endocrine therapy. Overall 5-year survival was 76% and 5-year breast cancer specific survival was 86%. Conclusion In selected group of ER+ LAPC patients, primary endocrine treatment achieves excellent survival outcome and is a viable alternative to other modalities of treatment.
- 1 October 2007
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 33 (8) , 972-976
Neoadjuvant chemotherapy in locally advanced primary breast cancers – The Nottingham experience
- 1 October 2007
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 33 (8) , 972-976
Neoadjuvant chemotherapy in locally advanced primary breast cancers – The Nottingham experience
- 1 July 2007
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 89 (5) , 494-496
Ultrasound-Guided, Vacuum-Assisted Excision in the Diagnosis and Treatment of Clinically Benign Breast Lesions
INTRODUCTION: Ultrasound-guided, vacuum-assisted biopsy has a definitive role in the diagnosis of breast lesions. Its role in the treatment of benign breast lesions like fibroadenomas has not been established. PATIENTS AND METHODS: This is a retrospective review of patients undergoing ultrasound-guided, vacuum-assisted biopsy for clinically benign breast lesions. The procedures were performed in all cases by two consultant radiologists with special interest in breast radiology between February 2002 and January 2004. Patients were followed up in the clinic 6 weeks after the procedure. RESULTS: Seventy-six patients had ultrasound-guided, vacuum-assisted excision of clinically benign breast lesions during this 2-year period. Mean age of the patients was 31 years. Altogether, 86 procedures were performed. Six patients with larger lesions (> 2 cm) had two procedures on separate sitting and 4 patients had separate lesions excised on a later date. Fifty-six patients were identified to have fibroadenomas and had complete excisions as evidenced on scan. Three out of nine patients identified with equivocal disease on fine needle aspiration cytology (FNAC) were found to have cancer following ultrasound-guided, vacuum-assisted excision. One patient who was diagnosed with cancer on FNAC, proved to be fibroadenoma on final histopathology. Four patients developed haematomas following ultrasound-guided, vacuum-assisted excision and all were managed conservatively. CONCLUSIONS: Our study shows that ultrasound-guided, vacuum-assisted excision can play an efficient role in the diagnosis of benign breast lesions and is a safe and successful alternative in treatment of fibroadenomas.
- 1 July 2007
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 89 (5) , 494-496
Ultrasound-Guided, Vacuum-Assisted Excision in the Diagnosis and Treatment of Clinically Benign Breast Lesions
INTRODUCTION: Ultrasound-guided, vacuum-assisted biopsy has a definitive role in the diagnosis of breast lesions. Its role in the treatment of benign breast lesions like fibroadenomas has not been established. PATIENTS AND METHODS: This is a retrospective review of patients undergoing ultrasound-guided, vacuum-assisted biopsy for clinically benign breast lesions. The procedures were performed in all cases by two consultant radiologists with special interest in breast radiology between February 2002 and January 2004. Patients were followed up in the clinic 6 weeks after the procedure. RESULTS: Seventy-six patients had ultrasound-guided, vacuum-assisted excision of clinically benign breast lesions during this 2-year period. Mean age of the patients was 31 years. Altogether, 86 procedures were performed. Six patients with larger lesions (> 2 cm) had two procedures on separate sitting and 4 patients had separate lesions excised on a later date. Fifty-six patients were identified to have fibroadenomas and had complete excisions as evidenced on scan. Three out of nine patients identified with equivocal disease on fine needle aspiration cytology (FNAC) were found to have cancer following ultrasound-guided, vacuum-assisted excision. One patient who was diagnosed with cancer on FNAC, proved to be fibroadenoma on final histopathology. Four patients developed haematomas following ultrasound-guided, vacuum-assisted excision and all were managed conservatively. CONCLUSIONS: Our study shows that ultrasound-guided, vacuum-assisted excision can play an efficient role in the diagnosis of benign breast lesions and is a safe and successful alternative in treatment of fibroadenomas.
- 30 September 2006
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (7) , 729-732
Comparative study of lymphoedema with axillary node dissection versus axillary node sampling with radiotherapy in patients undergoing breast conservation surgery
- 30 September 2006
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (7) , 729-732
Comparative study of lymphoedema with axillary node dissection versus axillary node sampling with radiotherapy in patients undergoing breast conservation surgery
- 28 February 2006
- Published by Elsevier in The Surgeon
- Vol. 4 (1) , 3-5
Surveillance colonoscopy in patients with colorectal cancer: How often should we be doing it?
- 28 February 2006
- Published by Elsevier in The Surgeon
- Vol. 4 (1) , 3-5
Surveillance colonoscopy in patients with colorectal cancer: How often should we be doing it?